Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.

Aerovate Therapeutics, a US-based pulmonary disease treatment developer backed by spinout-focused venture capital firm Osage University Partners, went public yesterday following an initial public offering that raised more than $121m. The company issued more than 8.68 million shares priced at $14 in its upsized offering on the Nasdaq Global Market, where it has listed under…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.